

मुंबईतील इंधन दर १२०.५१

BSE 56,819.39 -537.22

USD 1\$ ₹76.64

EURO 1€ ₹80.73

पाऊंड 1£ ₹96.05

दृष्टिक्षेपात

बजाज ऑटोला तिमाहीत १४६९ कोटी नफा...

डोअरस्टेप गोल्ड लोन ब्रँड आता महाराष्ट्रात...

लघु, सूक्ष्म उद्योगांचे १ मेपासून मुंबईत प्रदर्शन...

एलआयसी आयपीओ ४ मेपासून ९ मेपर्यंत होणार विक्री; ९०२-९४९ रुपयांदरम्यान किंमत पट्टा

मुंबई, ता. २७ : देरातील सर्वात मोठा आयपीओ म्हणून गजट असलेल्या भारतीय आयुर्विमा महामंडळाचा (एलआयसी) बहुप्रतिक्षित आयपीओ खेरील येत्या ४ मे रोजी दाखल होत आहे. एलआयसीच्या वतीने आज मुंबईत प्रकरण परिषदेत याची अधिकृत घोषणा करण्यात आली.



मुंबई : आयपीओबाबतची घोषणा बुधवारी करताना एलआयसीचे अध्यक्ष एम. आर. कुमार आणि 'दीपम'चे सचिव तुहिन पांडे.

याआधीचे सर्वात मोठे आयपीओ २०२ पेटीएम आयपीओ १८ हजार ३०० कोटी रुपये २०१० कोल इंडिया १५ हजार ५०० कोटी रुपये २००८ रिलायन्स पॉवर ११ हजार ७०० कोटी रुपये

Table with 2 columns: विक्री खुली होण्याची तारीख, विक्री बंद होण्याची तारीख, किंमत पट्टा, शेअर बाजारात नोंदणीची तारीख, लॉट साईज, छोटे गुंतवणूकदार व कर्मचारी सवलत, पॉलिस्वीकार सवलत

भांडवल बाजारातील सध्याचे वातावरण लक्षात घेता हा आयपीओ योग्य आकाराचा आहे. त्याला भांडवल पुरवठा कमी होणार नाही.

२०२१-२२ मधील ७८ हजार कोटीचे निवृत्तव्यक्तीचे उर्ध्व पूर्ण करण्यासाठी एलआयसीमधील सुमारे ३६.६ कोटी किंवा ५ टक्के भागभांडवल विकून सरकार ६० हजार कोटीहून अधिक भांडवल उभारण्याची सरकारची योजना होती. त्यानुसार फेब्रुवारीमध्ये सेवेकडे प्रस्ताव दाखल करण्यात आला होता.

एअर एशिया इंडिया खरेदीची एअर इंडियाची तयारी

मुंबई, ता. २७ : एअर इंडियाने दिलेल्या एअर एशिया इंडियाचे अधिग्रहण करण्याच्या प्रस्तावाला भारतीय स्पर्धा आयोगाने (सीसीआय) अधिसूचित केले आहे.

नव्या अधिसूचनेनुसार, एअर इंडिया एअर एशिया इंडियाचे संपूर्ण इन्व्हेस्टी शेर खरेदी करणार आहे. सध्या, टाटा समूहकडे एअर एशिया इंडियाच्या भाग भांडवलपैकी ८३.६७ टक्के हिस्सा आहे. या दोन्ही एअरलाइन्स टाटा समूहाचे चालवल्या जाताना, एअर इंडिया ही टाटा समूहाचा संपूर्ण मालकीची उपकंपनी आहे, तर एअरएशिया इंडियामध्ये मलेशियाच्या एअर एशियाच्या १६.३३ टक्के हिस्सा आहे. टाटाकडे मालकीहक्क एलआयसी आणि एअर इंडिया एअरलाइन्स आयपीओ २० टक्के विभागे देशांतगत मार्गावर चालविण्याचे बंधन आहे. त्यामुळे अशाप्रकारे तो नियम पाठला जाईल, अशीही चर्चा आहे.

सेन्सेक्समध्ये ५३७ अंशांची घसरण

मुंबई, ता. २७ : मंगळवारी वाढ दाखवणाऱ्या भारतीय शेअरबाजार निर्देशांकांनी आज एक टक्क्याच्या आसपास घसरण दाखविली व गेला दीड आठवडा साधारण त्याच पातळीत वर-खाली फिरत राहणाऱ्या परंपरा कायम राखली. आज सेन्सेक्स ५३७.२२ अंश, तर निफ्टी १६२.४० अंश घसरला.

३० शेअरपैकी २४ चे भाग कमी झाले, तर निफ्टीच्या ५० पैकी ३९ शेअरचे भाव घसरले. चॅनिंगमॉडेल लॉकडाऊन, रशिया-युक्रेन युद्ध व जागतिक बँकेचे कठोर धोरण, यामुळे अपेक्ष्यवस्था मंद होण्याच्या भीतीने गुंतवणूकदार विक्री करत असल्याची प्रतिक्रिया जि.ऑ.जि.त फायनान्सिअल सर्व्हिसेसचे विनोद नायर यांनी व्यक्त केली. आज सेन्सेक्सच्या प्रमुख शेअरपैकी फक्त टाटा स्टील एक टक्का, तर एशियन पेट पाऊण टक्का वाढला, टीएसएस अर्धा टक्का वाढला आणि एचसीएल टेक, रियायन्स इंडस्ट्रीज व एचडीएफसी बँक क्रिकोड वाढले.

खतांना ६१ हजार कोटीचे अंशदान

सकाळ न्यूज नेटवर्क नवी दिल्ली, ता. २७ : केंद्र सरकारने खरीप हंगामासाठी पोषक द्रव्य असलेल्या खातांवर सुमारे ६१ हजार कोटी रुपयांचे अंशदान देण्याचा निर्णय घेतला आहे. याखेरीज नक्षत्रवादी हिंसाचारप्रति भारतीय सुरक्षा दृष्टीने महत्त्वाच्या केंद्रांची संपर्क व्यवस्था '२ जी' वरून '४ जी' मध्ये स्थापित करण्याचेही सरकारने ठरविले असून पथरीवाल्यांसाठी सुरु केलेल्या पंतप्रधान स्वनिधीला (स्ट्रीटव्हेड आत्मनिर्भर निधी) डिसेंबर २०२४ पर्यंतची मुदतवाढ केंद्र सरकारने दिली आहे.

पत्रकारांनी बोलताना सांगितले, की यंदच्या खरीप हंगामासाठी एप्रिल ते सप्टेंबर या सहा महिन्यांच्या कालावधीसाठी कॉम्पेट आणि पोर्टेय या खातांसाठी पोषक द्रव्य आधारीत अंशदानाला मंजुरी दिली आहे. या अंशदानासाठी ६०,९३९.२३ कोटी रुपये खर्च येणार आहे. या खातांवर मार्गाल कर्षणाच्या तुलनेत यंदा अंशदानात प्रती थैली ५० टक्क्यांनी वाढ झाली आहे. नक्षत्रवाद्यांच्या हिंसाचाराचा उपद्रव असलेल्या महाराष्ट्रासह आंध्र प्रदेश, बिहार, तेलंगण आदी दहा राज्यांमध्ये २५४२ मोबाईल टॉवर '२ जी' तंत्रज्ञानाऐवजी '४ जी' तंत्रज्ञानाला प्रदान करावयासाठी अद्यावत करण्यात महामंडळाचे शिक्षामोर्तव केले. यासाठी २४२६ कोटी रुपये खर्च होणार आहे. यात महाराष्ट्रात १२५ मोबाईल टॉवरचे अद्ययावतीकरण केले जाणार आहे.

sanofi सनोफी इंडिया लिमिटेड नोंदणीकृत कार्यालय: सनोफी हॉटेल, सीटीएस क्र. 117-बी, एल.ए.डी. बिल्डिंग पार्क, बाकी विहार रोड, पर्व, मुंबई-400072

KANSAI PAINT NEROLAC कॅन्साई नेरोलॅक पेंटस् लिमिटेड नोंदणीकृत कार्यालय: नेल्सॉन हिल्स, गणतंत्राचा कक्ष मार्ग, लोअर फ्लोर, मुंबई-४०००१३

'द्विटर'च्या धोरणकर्त्या विजया गड्डे निशाण्यावर सेन्सॉरशिपवर मस्क यांचा सवाल

न्यूयॉर्क, ता. २७ (वृत्तसंस्था) : 'द्विटर'चे संस्थापक एलॉन मस्क यांच्याकडे द्विटरचा ताबा आल्यानंतर मुख्य कार्यकारी अधिकारी पदपत्र अग्रवाल यांना कंपनीतून बाहेर पडावे लागेल, अशी चर्चा मंगळवारी (ता. २६) सुरू होती. आता द्विटरच्या धोरण विभागाच्या प्रमुख विजया गड्डे या निशाण्यावर आहेत. द्विटरच्या सेन्सॉरशिपसंबंधीच्या निर्णयांना गड्डे जबाबदार असल्याचे मानले जात आहे. अमेरिकेचे माजी अध्यक्ष डोनाल्ड ट्रंप यांचे द्विटर अकाऊंट बंद करण्याचा निर्णयही त्यांनीच घेतला होता. मस्क यांनी द्विटरचे संपूर्ण हक्क विकत घेतल्यानंतर झालेल्या संचालक मंडळाच्या बैठकीत विजया गड्डे भावुक झाल्या व रडू लागल्याचे सांगण्यात येत आहे. मस्क यांनी विजया गड्डे यांच्या सेन्सॉरशिपच्या धोरणावर सवाल उपस्थित केला आहे. मस्क आणि ट्रंप यांचे चाहते गड्डे

'न्यूयॉर्क पोस्ट'चेही अकाऊंट बंद अमेरिकेचे अध्यक्ष जो बायडेन यांचे पुत्र हंटर बायडेन यांच्या लॅपटॉपवर केलेल्या विशेष वृत्तांमुळे 'न्यूयॉर्क पोस्ट' या वृत्तपत्राचे द्विटर अकाऊंट बंद केले होते. मस्क यांनी याप्रकरणी गड्डे यांच्यावर टीका करित हा अत्यंत चुकीचा निर्णय असल्याचे म्हटले होते. एक खरे वृत्त प्रसारित केल्याने नाताजालेल्या वृत्तपत्राचे द्विटर अकाऊंट बंद करण्याचा निर्णय चुकीचा आहे, असे मस्क यांनी पोडकास्ट निवेदक सागर एजेटी यांच्या द्विटरला उत्तर देताना म्हटले होते.

ट्रेडर गड्डे यांच्यावर सोशल मीडियावर टीका करित आहेत. भारतात जमलेल्या विजया गड्डे यांनी २०११ मध्ये द्विटरमध्ये काम करण्यास सुरुवात केली होती. तेव्हापासून कंपनीच्या कायदे व धोरणासंबंधीची जबाबदारी त्या सांभाळत आहेत.



विजया गड्डे

Table with 6 columns: अ.नं., प्रक्षेत्राचे नाव, आंबा बाग क्र., बागेतील झाडे (बाण), फळधारणा झालेल्या झाडांची संख्या, अनामत रक्कम, निविदा फॉर्म फी रुपये (विना परतवा)

Table with 5 columns: क्र., तपशील, तिमाहीअखेर ३१.०३.२०२२, मागील तिमाहीअखेर ३१.१२.२०२१, संचिंतित तिमाहीअखेर ३१.०३.२०२१, चालू वर्षाअखेर ३१.०३.२०२२, मागील वर्षाअखेर ३१.०३.२०२१

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU # 3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."


The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. **PTI**

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofiindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofiindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes:

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited
Sd/-
Rajiv Sabharwal
Managing Director & CEO
DIN: 00057333

Place: Mumbai

Date: April 26, 2022

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy:

★ ★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9



Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. **PTI**

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Rupees in Million

Particulars	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022 (Audited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debt Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes:

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS.”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said.

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4				3	6	9	7	
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes:-

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022



Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. **PTI**

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU # 3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794
Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debt Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022



Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

NOTICE FOR CHANGE OF REGISTERED OFFICE OF M/S. ADIDEV WAREHOUSE LLP FROM NCT OF DELHI TO THE STATE OF HARYANA.

BEFORE THE REGISTRAR OF COMPANIES, DELHI

In the matter of the sub-section (3) of section 13 of Limited Liability Partnership Act, 2008 and Rule 17 of the Limited Liability Partnership Rules, 2009 AND in the matter of M/S. ADIDEV WAREHOUSE LLP (LLPIN: AAF-6985) having its registered office at Khasra No. 21/13/2 E Block, Gali No. 7, Burari Road, Swaroop Nagar Delhi North West DL 110042 IN.

Notice is hereby given to the General Public that the LLP proposes to make an application to Registrar of Companies, Delhi under section 13 (3) of the Limited Liability Partnership Act, 2008 seeking permission to change its Registered office from the 'NCT of Delhi to the State of Haryana.'

Any person whose interest is likely to be affected by the proposed change of the registered office of the LLP may deliver or cause to be delivered or send by Registered post of his/her objections supported by an affidavit stating the nature of his/her interest and grounds of opposition to the Registrar of Companies, Delhi, "at 4th Floor, IFCI Tower, 61, Nehru Place, New Delhi 110019" within twenty-one (21) days from the date of publication of this notice with a copy to the LLP at its registered office at the address mentioned above.

For and on behalf of
ADIDEV WAREHOUSE LLP
Sd/-
ANITA YADAV

Date : 28.04.2022 (Designated Partner)
Place : New Delhi DIN: 07395738

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Website - www.sanofiindia.com | CIN No - L24239MH1956PLC009794
Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofiindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4				3	6	9	7	
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670
Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013
Tel.: 022 6606 9000 • Fax: 022-66562699
Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debt Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited
Sd/-
Rajiv Sabharwal
Managing Director & CEO
DIN: 00057333

Place: Mumbai
Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."


The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU # 3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4				3	6	9	7	
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794
Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Rupees in Million

Particulars	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022 (Audited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. **PTI**

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU # 3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4				3	6	9	7	
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy:
★★
Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794
Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes:-

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-
Rajiv Sabharwal
Managing Director & CEO
DIN: 00057333

Place: Mumbai

Date: April 26, 2022



Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited
Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."


The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU # 3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4				3	6	9	7	
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy:
★★
Solution
tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Website - www.sanofiindia.com | CIN No - L24239MH1956PLC009794
Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Notes:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofiindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited

Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2021	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

- The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).
- For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.
- The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-
Rajiv Sabharwal
Managing Director & CEO
DIN: 00057333

Place: Mumbai

Date: April 26, 2022



Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofiindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Notes:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofiindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited

Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022

Vaccination of eligible children a priority: PM

It's clear that Covid-19 is not fully over, Modi says in meet with CMs

SOHINI DAS
Mumbai, 27 April

Prime Minister Narendra Modi met chief ministers of states on Wednesday to review the increase in Covid cases across the country.

The PM said vaccinating all eligible children at the earliest is a priority for the government and specialised programmes are needed to be conducted in schools to achieve this feat.

Modi asserted, "It is clear that the corona challenge is not fully over."

The PM said Omicron and its sub-variants can create problems as evident by the case of many countries of Europe. The sub-variants are causing many surges in many countries. The PM said India had been able to handle the situation better than many countries, but the increasing cases in some states in the last two weeks show that we need to stay alert.

Citing the rise in Covid-19 cases in some states in the last two weeks, he said there was a need to remain alert. He spoke about the need for states to regularly monitor and report data, maintain effective surveillance, upgrade infrastructure and utilise funds given by the Centre.

He added, "Our priority is to vaccinate all eligible children at the earliest. Special campaigns will also be needed in schools. Teachers and parents should be aware of this."

The Prime Minister mentioned that schools have opened after a long time and a lot of parents are worried by the increased number of cases in some places. On Tuesday, the Drugs Controller General of India (DCGI) approved two vaccines — Covaxin and Corbevax — for use in children below 12 years.

"There were no plans yet to include children below 12 years in

“OUR PRIORITY IS TO VACCINATE ALL ELIGIBLE CHILDREN AT THE EARLIEST. SPECIAL CAMPAIGNS WILL ALSO BE NEEDED IN SCHOOLS. TEACHERS, AND PARENTS SHOULD BE AWARE OF THIS”

NARENDRA MODI
Prime Minister



2nd dose, booster gap may be 6 mths soon

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI), which is set to hold a meeting on April 29, they told PTI. Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. "Taking into account the scientific evidence and findings of the studies done and internationally, the gap between the second dose of Covid-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday," a source in the know of the developments said. PTI

the vaccination drive. There is no scientific evidence about their vulnerability," sources in the Union Ministry of Health said.

"Our scientists and experts are continuously monitoring the national and global situation. We have to work on their suggestions with a pre-emptive, pro-active and collective approach," the PM said in the review meeting.

He stressed on the strategy of test, track and treat. In the current situation of coronavirus, it is necessary that we have a 100 per cent RT-PCR test for patients admitted in hospitals who are serious influenza cases.

Several chief ministers, includ-

ing West Bengal's Mamata Banerjee, Chhattisgarh's Bhupesh Baghel, Delhi's Arvind Kejriwal and Punjab's Bhagwant Mann, participated in the interaction.

Kejriwal said in recent days, Delhi witnessed a high positivity rate. He also spoke about masks having been made mandatory again. Haryana Chief Minister said a high number of cases in the state is mainly being seen around Delhi, in Gurugram and Faridabad.

India recorded 2,927 fresh infections in a day which pushed the case tally to 43,065,496 while the active caseload increased to 16,279, according to Union Health Ministry data on Wednesday.

▶ FROM PAGE 1

Ambuja buy...

Damani, who started as a stock broker, prefers to keep a low profile and has seldom talked about his investment plans. Apart from India Cements, he holds stakes in VST Industries and Andhra Paper.

According to bankers, both the Adani group, which is the front runner to buy Ambuja, and the JSW group are talking to various private equity funds and banks to tie up finances for the bid, which would cost them as high as \$10 billion (about ₹76,000 crore), including the open offers for Ambuja and its subsidiary ACC. "Damani is not only a strong financial partner but can also bring in other financial partners who want a piece of the cake," the banker quoted above said.

Damani has a close partnership with former Enam Group founders like Vallabh Bhansali and Nemish Shah, who have a stock portfolio worth billions of dollars.

Ultratech, the banker said, is a dark horse, which may make a bid for the company with the Aditya Birla group raising funds by diluting a minority stake in their cement flagship to raise ₹20,000 crore, and the rest via debt. "There may be a Competition Commission of India objection with Ultratech acquiring Ambuja Cements, but they can always sell the overlapping plants in western India," the banker said. Ultratech did not comment on the market speculation. Ultratech will retain the number one position with 120 million tonnes a year capacity. The acquisition of Ambuja Cements and its subsidiary will give the acquirer a 64 million tonnes a year capacity.

Anil Singhvi, former cement industry veteran, said the sale of the India business by Holcim is a good transaction for the cement major, which will be able to raise \$6-7 billion and reduce its debt substantially. "Holcim

did not grow its India business in the last 15 years and it makes sense for them to sell it to the highest bidder and de-leverage at the parent level," Singhvi said.

Holcim will be announcing the winning bid within a week just around its annual shareholders meeting on May 4th.

Holcim controls 63.1 per cent of Ambuja Cements, which was worth ₹48,136 crore as of Wednesday. Shares of Ambuja closed at ₹385 apiece while ACC closed at ₹2,350 a share.

Global funds...

The I-T department observes irregularities in tax filings of 2013-14, 2014-15, and 2015-16.

DRP, set up by the Central Board of Direct Taxes, is an alternative resolution mechanism to facilitate expeditious resolution in tax matters for foreign companies.

Foreign investors typically opt for a dispute resolution mechanism to achieve certainty on tax disputes arising from cross-border transactions.

Unlike other prolonged proceedings, DRP proceedings are time-bound; their decisions are binding on both the assessee and the department, against which no appeal can be filed, barring exceptions, said a senior tax official.

On the other hand, proceedings of CIT(A) are not time-bound — 20 per cent of the tax demand is required to be made upfront. No such payment is required in the case of DRP applications. Also, the panel has to adjudicate the matter within nine months.

Those opting for CIT(A) have to file an application within 30 days from receipt of the final order — which is the confirmation of the draft order.

The only drawback to the resolution panel is that there is no appeal in case the ruling goes against the assessee, which happens often unless there are strong legal grounds, said another person.

Sources say that the tax department is confident of a favourable ruling in the matter as there is evidence supporting fiscal evasion of taxes by means of treaty shopping.

While investing in Indian companies, most PE funds either take the traditional route to invest directly as foreign direct investment or set up a special purpose vehicle outside India — usually in a tax-friendly jurisdiction.

At present, PE funds based in India are subject to capital gains tax. These PE funds deal with unlisted companies and attract long-term capital gains at 10 per cent, while short-term is levied at 30-40 per cent.

The draft order issued by the department to several global fund houses proposed net long-term capital gains at the rate of 20 per cent on transfer of unlisted shares of the Indian company to another entity. It also issued a penalty notice on income under-reported.

Tax experts believe that the said tax order has overridden the position taken by the Supreme Court in the ruling of Azadi Bachao Andolan, where the tax residency certificate (TRC) was conclusive evidence of a foreign entity.

"More so, these assessments have been concluded for the same facts in subsequent or preceding years and would cause needless litigation," said Mumbai-based chartered accountant Mitil Chokshi.

However, the tax department holds the right to deny TRC of an entity if it is found abusing tax treaty benefits and indulging in treaty shopping. Most of the investment was routed through Mauritius and Cyprus during the assessment years. However, the treaty was amended in 2017.

BS SUDOKU

3649

		2			7			
		3					5	9
1			9				4	
		6						
	9		8				1	
4					3	6	9	7
	3			6			7	
		4						5
6	5				1	9		4

SOLUTION TO #3648

5	8	2	1	6	3	4	9	7
7	3	4	5	9	2	8	6	1
1	9	6	8	4	7	2	5	3
2	1	8	6	5	9	3	7	4
6	4	3	7	2	8	9	1	5
9	7	5	4	3	1	6	8	2
8	5	9	3	7	4	1	2	6
3	2	7	9	1	6	5	4	8
4	6	1	2	8	5	7	3	9

Easy: ★★

Solution tomorrow

HOW TO PLAY

Fill in the grid so that every row, every column and every 3x3 box contains the digits 1 to 9

sanofi

SANOFI INDIA LIMITED

Registered Office: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Website - www.sanofiindia.com | CIN No - L24239MH1956PLC009794

Tel No. - (022)28032000 | Fax No. - (022)28032939 | Email - IGRC.SIL@sanofi.com

Extract of unaudited financial results for the quarter ended 31st March 2022

Particulars	Rupees in Million		
	Quarter Ended 31.03.2022	Year Ended 31.12.2021	Quarter Ended 31.03.2021
Total income from operations	7,070	29,566	7,251
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2,076	7,684	1,949
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,257	12,576	1,949
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	2,384	9,444	1,459
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,384	9,411	1,459
Equity Share Capital	230	230	230
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	22,026	-
Basic and diluted earnings (per share Rs 10/- each)	103.51	410.06	63.35

Note:

The above is an extract of the detailed format of the unaudited financial results for the quarter ended 31st March 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results is also available on the websites of the Company (www.sanofiindia.com) and of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

Date: 26th April 2022
Place: Mumbai

Sanofi India Limited

Vaibhav Karandikar
Whole Time Director & CFO



TATA CAPITAL LIMITED

Corporate Identity Number: U65990MH1991PLC060670

Registered Office: 11th Floor, Tower A, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

Tel: 022 6606 9000 • Fax: 022-66562699

Website: www.tatacapital.com • Email: investors@tatacapital.com

Extract of Financial Results for the quarter and year ended March 31, 2022

(Rs. in lakh)

Sr. No.	Particulars	Standalone				Consolidated	
		For the Quarter ended		For the year ended		For the year ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	20,309	18,093	51,189	45,217	10,25,265	9,98,772
2	Net profit/(loss) for the period (before tax, exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
3	Net profit/(loss) for the period before tax (after exceptional items)	9,454	6,862	10,295	6,303	2,34,772	1,61,497
4	Net profit/(loss) for the period after tax (after exceptional items)	7,629	4,925	8,310	4,667	1,80,081	1,24,464
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	7,569	4,645	8,211	5,355	1,85,134	1,24,228
6	Paid up Equity Share Capital (Face value : Rs. 10 per share)	3,51,617	3,51,617	3,51,617	3,51,617	3,46,335	3,46,360
7	Reserves (excluding Revaluation Reserve)	3,50,181	3,41,260	3,50,181	3,41,260	8,24,971	6,50,940
8	Securities Premium Account	2,95,866	2,95,866	2,95,866	2,95,866	2,93,214	2,93,323
9	Net worth	8,12,353	8,08,083	8,12,353	8,08,083	12,54,096	10,88,168
10	Paid up Debt Capital / Outstanding Debt	2,98,134	2,29,244	2,98,134	2,29,244	86,29,495	69,16,137
11	Outstanding Redeemable Preference Shares	1,10,983	1,15,740	1,10,983	1,15,740	1,11,008	1,15,895
12	Debt Equity Ratio	0.37	0.28	0.37	0.28	6.88	6.36
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	- Basic*	0.22	0.14	0.24	0.13	4.69	3.20
	- Diluted*	0.22	0.14	0.24	0.13	4.69	3.20
14	Capital Redemption Reserve	575	575	575	575	575	575
15	Debenture Redemption Reserve	-	-	-	-	30,000	30,000
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA	NA

* Not annualised for the quarter ended March 31, 2022 and March 31, 2021

Notes: -

1 The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange under Regulation 52 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the National Stock Exchange of India Limited (www.nseindia.com) and the website of the Company (www.tatacapital.com).

2 For the other line items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the National Stock Exchange of India Limited and can be accessed on www.nseindia.com.

3 The Group prepares the Consolidated Financial Results on an Annual basis.

For Tata Capital Limited

Sd/-

Rajiv Sabharwal

Managing Director & CEO

DIN: 00057333

Place: Mumbai

Date: April 26, 2022